BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Bausch Health Companies Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$6.32+0.02 (+0.32%)
Close on Oct 19, 2026
- Market cap
- $2.39B
- P/E (TTM)
- –
- Dividend yield
- –
Bausch Health Companies Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch + Lomb | $5.32B | $5.21B | $5.10B | $4.98B | $4.89B | $4.83B | $4.79B | $4.68B | $4.50B | $4.31B | $4.15B | $3.97B | 49.1% | +8.9% |
| Salix | $2.81B | $2.68B | $2.58B | $2.52B | $2.45B | $2.38B | $2.33B | $2.28B | $2.25B | $2.25B | $2.25B | $2.25B | 25.9% | +14.8% |
| International | $1.18B | $1.16B | $1.13B | $1.11B | $1.11B | $1.11B | $1.11B | $1.12B | $1.11B | $1.09B | $1.07B | $1.04B | 10.9% | +6.5% |
| Diversified | $917.00M | $917.00M | $937.00M | $910.00M | $921.00M | $953.00M | $950.00M | $981.00M | $971.00M | $948.00M | $943.00M | $940.00M | 8.4% | -0.4% |
| Solta Medical | $624.00M | $576.00M | $518.00M | $519.00M | $491.00M | $465.00M | $440.00M | $405.00M | $376.00M | $362.00M | $347.00M | $343.00M | 5.7% | +27.1% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix | $2.17B | $2.02B | $1.93B | $1.86B | $1.72B | $1.64B | $1.60B | $1.56B | $1.55B | $1.56B | $1.55B | $1.55B | +26.1% |
| Bausch + Lomb | $1.31B | $1.22B | $1.13B | $1.04B | $1.02B | $1.05B | $1.11B | $1.08B | $1.04B | $1.01B | $980.00M | $933.00M | +28.3% |
| Diversified | $615.00M | $612.00M | $627.00M | $605.00M | $612.00M | $639.00M | $626.00M | $638.00M | $621.00M | $593.00M | $586.00M | $579.00M | +0.5% |
| International | $349.00M | $337.00M | $334.00M | $351.00M | $366.00M | $374.00M | $376.00M | $377.00M | $363.00M | $345.00M | $335.00M | $318.00M | -4.6% |
| Solta Medical | $291.00M | $254.00M | $232.00M | $250.00M | $233.00M | $226.00M | $213.00M | $187.00M | $167.00M | $165.00M | $161.00M | $161.00M | +24.9% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $10.75B | $10.43B | $10.16B | $9.92B | $9.74B | $9.62B | $9.52B | $9.37B | $9.10B | $8.87B | $8.66B | $8.45B | 99.1% | +10.4% |
| Other revenues | $103.00M | $102.00M | $110.00M | $113.00M | $117.00M | $115.00M | $107.00M | $102.00M | $99.00M | $96.00M | $94.00M | $93.00M | 0.9% | -12.0% |
| Price Appreciation Credit | $36.00M | $18.00M | $18.00M | $21.00M | $20.00M | $20.00M | $18.00M | $11.00M | $11.00M | $11.00M | $11.00M | $10.00M | 0.3% | +80.0% |
| Devices | – | – | – | – | – | – | $2.24B | $2.15B | $2.08B | $2.03B | $2.00B | $1.97B | – | – |
| Branded and Other generics | – | – | – | – | – | – | $979.00M | $977.00M | $995.00M | $980.00M | $960.00M | $967.00M | – | – |
| OTC | – | – | – | – | – | – | $1.90B | $1.88B | $1.87B | $1.84B | $1.80B | $1.75B | – | – |
| Pharmaceuticals | – | – | – | – | – | – | $4.40B | $4.36B | $4.16B | $4.02B | $3.91B | $3.76B | – | – |
| Other revenues | – | – | – | – | – | – | $107.00M | $101.00M | $98.00M | $96.00M | $94.00M | $93.00M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mexico | – | – | – | – | – | – | $315.00M | $336.00M | $338.00M | $329.00M | $322.00M | $310.00M | – | – |
| Canada | – | – | – | – | – | – | $402.00M | $391.00M | $379.00M | $372.00M | $366.00M | $361.00M | – | – |
| Poland | – | – | – | – | – | – | $350.00M | $343.00M | $333.00M | $330.00M | $319.00M | $306.00M | – | – |
| Russia | – | – | – | – | – | – | $161.00M | $160.00M | $153.00M | $150.00M | $148.00M | $164.00M | – | – |
| Japan | – | – | – | – | – | – | $188.00M | $185.00M | $186.00M | $187.00M | $194.00M | $197.00M | – | – |
| China | – | – | – | – | – | – | $496.00M | $477.00M | $458.00M | $450.00M | $441.00M | $435.00M | – | – |
| France | – | – | – | – | – | – | $230.00M | $223.00M | $220.00M | $218.00M | $214.00M | $213.00M | – | – |
| Germany | – | – | – | – | – | – | $159.00M | $158.00M | $152.00M | $153.00M | $152.00M | $154.00M | – | – |
| Other | – | – | – | – | – | – | $1.08B | $1.07B | $1.05B | $1.03B | $1.01B | $972.00M | – | – |
| U.S. | – | – | – | – | – | – | $5.77B | $5.68B | $5.51B | $5.34B | $5.19B | $5.05B | – | – |
| United Kingdom | – | – | – | – | – | – | $135.00M | $133.00M | $131.00M | $128.00M | $125.00M | $122.00M | – | – |
| Italy | – | – | – | – | – | – | $94.00M | $93.00M | $90.00M | $89.00M | $86.00M | $80.00M | – | – |
| South Korea | – | – | – | – | – | – | $146.00M | $126.00M | $112.00M | $101.00M | $93.00M | $88.00M | – | – |
| Spain | – | – | – | – | – | – | $99.00M | $96.00M | $95.00M | $93.00M | $92.00M | $90.00M | – | – |
From the segment and revenue-disaggregation notes of Bausch Health Companies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.